The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of neoadjuvant immunotherapy with durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (gemcitabine/cisplatin or carboplatin) in patients with operable high-risk upper tract urothelial carcinoma.
 
Nadine Houede
No Relationships to Disclose
 
Thierry Chevallier
No Relationships to Disclose
 
Jaffrelot Loic
No Relationships to Disclose
 
Constance Thibault
Honoraria - AAA/Endocyte/Novartis; Accord Healthcare; Amgen; Astellas Pharma; AstraZeneca; Bristol Myers Squibb; Gilead Sciences; Ipsen; Janssen Oncology; Merck; MSD Oncology; Pfizer; Sanofi; Seagen
Consulting or Advisory Role - AAA/Endocyte/Novartis; AstraZeneca; Bristol-Meyers Squibb; Gilead Sciences; Ipsen; Janssen Oncology; Merck; MSD Oncology; Pfizer
Research Funding - AstraZeneca (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Janssen Oncology; MSD Oncology; Pfizer
 
Neuzillet Yann
No Relationships to Disclose
 
Christine Abraham Jaillon
No Relationships to Disclose
 
Alexandra Masson-Lecomte
No Relationships to Disclose
 
Gwenaelle Gravis
Consulting or Advisory Role - Amgen (Inst); Bayer (Inst); BMS (Inst); Curium Pharma (Inst); Janssen (Inst); Merck/Pfizer (Inst)
Speakers' Bureau - Advanced Accelerator Applications (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BMS (Inst); Ipsen (Inst); Janssen Oncology (Inst); Pfizer/EMD Serono (Inst)
Research Funding - BMS (Inst)
Expert Testimony - BAYER (Inst); Pfizer/EMD Serono (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen Oncology; Pfizer
 
Sophie Tartas
No Relationships to Disclose
 
Damien Pouessel
Honoraria - AAA/Endocyte/Novartis; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; MSD Oncology; Pfizer/Astellas
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb/Medarex; Eisai; Merck; MSD Oncology; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen Oncology; Pfizer
 
Brigitte Laguerre
Honoraria - Astellas Pharma; Bayer; Bayer; Bayer; Bayer; Bayer; Eisai; Eisai; Janssen Oncology; Janssen Oncology; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; BMS; IPSEN; Ipsen; Janssen Oncology; MSD Oncology; Novartis AAA; Pfizer; Pfizer; Pfizer
 
Francois Audenet
No Relationships to Disclose
 
Evanguelos Xylinas
No Relationships to Disclose
 
Luquiens Guillaume
No Relationships to Disclose
 
Morgan Roupret
Consulting or Advisory Role - Arquer Diagnostics; GlaxoSmithKline; Intuitive Surgical; Ipsen; Janssen-Cilag; Lilly; MSD; Roche; Sanofi; Takeda
Travel, Accommodations, Expenses - Astellas Pharma; Coloplast